UCB (BRSE:UNC) - Cotización, noticias y análisis

Resumen de acción UNC

A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. Saber más

Análisis fundamental de UNC
Puntuación del snowflake
Valoración	3/6
Crecimiento futuro	4/6
Rendimiento pasado	2/6
Salud financiera	4/6
Dividendos	4/6

Recompensas

Cotiza un 46.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 24.84%

Análisis de riesgos

Acciones altamente ilíquidas

Los márgenes de beneficio (7.7%) son inferiores a los del año pasado (18.3%)

Competidores de UCB SA

Dottikon ES Holding

SWX:DESN

CHF 3.3b

Novartis

SWX:NOVN

CHF 183.8b

Roche Holding

SWX:ROG

CHF 204.1b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de UCB
Precios históricos de las acciones
Precio actual de la acción	€77.91
Máximo en las últimas 52 semanas	€0
Mínimo de 52 semanas	€0
Beta	0.33
1Cambio en 1 mes	0%
Variación en 3 meses	n/a
Cambio de 1 año	n/a
3Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	-13.69%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	UNC	CH Pharmaceuticals	Mercado CH
7D	0%	0.6%	0.5%
1Y	n/a	8.5%	6.3%

Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de UNC en comparación con la industria Swiss Pharmaceuticals.

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de UNC frente al mercado Swiss.

Volatilidad de los precios

Is UNC's price volatile compared to industry and market?
UNC volatility
UNC Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	2.8%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.8%
10% least volatile stocks in CH Market	1.6%

Precio estable de las acciones: UNC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de UNC en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1925	8,406	Jean-Christophe Tellier	www.ucb.com

Resumen de fundamentos de UCB SA

¿Cómo se comparan los beneficios e ingresos de UCB con su capitalización de mercado?
Estadísticas fundamentales de UNC
Capitalización bursátil	CHF 16.10b
Beneficios(TTM)	CHF 414.50m
Ingresos (TTM)	CHF 5.38b

38.8x

Ratio precio-beneficio (PE)

3.0x

Ratio precio-ventas (PS)

¿Está UNC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de UNC
Ingresos	€5.45b
Coste de los ingresos	€1.67b
Beneficio bruto	€3.77b
Otros gastos	€3.35b
Beneficios	€420.00m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	2.22
Margen bruto	69.27%
Margen de beneficio neto	7.71%
Ratio deuda/patrimonio	30.5%

¿Cómo se ha desempeñado UNC a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.5%

Rentabilidad actual por dividendo

60%

Ratio de pagos

¿Paga UNC dividendos fiables?

Ver historial de dividendos e índices de referencia de UNC

¿Cuándo hay que comprar UNC para recibir un próximo dividendo?
fechas de dividendos de UCB
Fecha ex dividendo	Apr 28 2023
Fecha de pago de dividendos	May 03 2023
Días hasta ex dividendo	579 days
Días hasta la fecha de pago de dividendos	574 days

¿Paga UNC dividendos fiables?

Ver historial de dividendos e índices de referencia de UNC

Resumen de acción UNC

Recompensas

Análisis de riesgos

Competidores de UCB SA

SWX:DESN

CHF 3.3b

SWX:NOVN

CHF 183.8b

SWX:ROG

CHF 204.1b

SWX:COPN

CHF 1.0b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

Investor sentiment deteriorated over the past week

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results